- Report
- March 2025
- 200 Pages
Global
From €3966EUR$4,490USD£3,387GBP
- Report
- February 2025
- 200 Pages
Global
From €3966EUR$4,490USD£3,387GBP
- Report
- January 2023
- 154 Pages
From €3047EUR$3,450USD£2,603GBP
- Report
- June 2025
- 50 Pages
Global
From €2340EUR$2,650USD£1,999GBP
Atovaquone is an antibiotic used to treat a variety of infectious diseases, including malaria, toxoplasmosis, and pneumocystis pneumonia. It is a synthetic quinone compound that works by inhibiting the production of mitochondrial energy in the parasites that cause these diseases. Atovaquone is available in both oral and intravenous formulations, and is often used in combination with other drugs to increase its effectiveness. It is generally well-tolerated, with few side effects.
Atovaquone is a widely used drug in the treatment of infectious diseases, and is available from a number of pharmaceutical companies. Some of the major players in the market include GlaxoSmithKline, Merck, Pfizer, and Sanofi. Other companies that produce atovaquone include Bristol-Myers Squibb, Novartis, and Teva Pharmaceuticals. Show Less Read more